CD Tesis

Analisis Dan Evaluasi Nilai Ejection Fraction Terhadap Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil Yang Mendapatkan Kemoterapi Dengan Rejimen Paklitaksel Dan Karboplatin Di RSUD Arifin Achmad Provinsi Riau

---

Non-small cell lung cancer accounts for 80-85% of all lung
cancers. Cardiotoxicity is one of the most serious side effects of chemotherapy.
Screening of patients before treatment and monitoring of cardiac function during
conventional therapy by looking at the value of the ejection fraction. This study
aims to determine the incidence of cardiotoxicity from chemotherapy with
paclitaxel and carboplatin regimens for NSCLC in AA Hospital, Riau Province.
Methods : This study is a retrospective cohort analytic study using an
observational study design by looking at the medical records of NSCLC patients
treated from October 2021 – March 2022 which aims to see changes in the value
of ejection fraction in NSCLC patients receiving chemotherapy with paclitaxel
and carboplatin regimens.
Results : This study involved 25 respondents who underwent chemotherapy, then
underwent an EF examination. The patient's EF rate before chemotherapy was
72.0 ± 6.6%, after the third chemotherapy was 67.5 ± 11.2%, and after the sixth
chemotherapy was 64.6 ± 11.2. This figure shows that the mean EF of the patients
in this study tends to decrease from before chemotherapy to after the third
chemotherapy and after the third and sixth chemotherapy tends to decrease as
well. Ejection fraction among patients with adenocarcinoma and SCC. EF levels
in patients with SCC before (SSC: 71.7 ± 7.2 vs 72.3 ± 6.0, p = 0.364), after the
third cycle (SSC: 65.2 ± 6.3 vs. 63.2 ± 6 .3, p = 0.774) and after the sixth cycle
(SSC: 65.2 ± 4.1 vs. 60.1 ± 5.6, p = 0.333) were greater than patients with
adenocarcinoma. The EF level data used in this study were normally distributed,
so that the paired difference test used was a parametric test, using paired t-test.
There was a difference between EF levels before and after the third chemotherapy
(p < 0.001), as well as after the third and sixth chemotherapy (p = 0.002).
Conclusion : There was a difference between EF levels before and after the third
chemotherapy (p < 0.001), as well as after the third chemotherapy and after the
sixth chemotherapy (p = 0.002). There was a significant reduction in EF in those
taking paclitaxel and carboplatin chemotherapy regimens, but did not reach the
threshold for systolic dysfunction or heart failure. There was no significant
difference between the EF of patients with no comorbidities and patients with
comorbid heart failure and DM either before chemotherapy, after the third cycle
or after the sixth cycle.
Keyword :. NSCLC, Paclitaxel, Carboplatin, Ejection Fraction

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

1810246594

Penerbit

Pekanbaru : Universitas Riau – Pascasarjana – Tesis Pulmonologi Dan Kedokteran Respirasi., 2022

Deskripsi Fisik

-

Bahasa

Indonesia

ISBN/ISSN

-

Klasifikasi

1810246594

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

-

Info Detail Spesifik

-

Pernyataan Tanggungjawab

FATAH

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar